BEAM — Suntory Global Spirits
Unknown Industry · Unknown Sector
Beam Therapeutics Inc. is a biotechnology company dedicated to developing a new class of precision genetic medicines based on its proprietary base editing technology, offering lifelong curative treatments for patients with serious diseases. The company focuses on its hematology and genetic disease portfolio programs, with a pipeline that includes multiple candidates such as: BEAM-101 for the treatment of sickle cell disease, BEAM-302, a liver-directed lipid nanoparticle drug for the treatment of alpha-1 antitrypsin deficiency; as well as other candidates including BEAM-103 and BEAM-104. The company operates and manages its business under a single operating segment and conducts operations solely in the United States.
Industry Peers
—
Sector Peers
—
Key Facts
| Status | Active |
| Sector | Unknown Sector |
| Industry | Unknown Industry |
| Joined | 1957-03-04 |
| Tenure | 57 yrs |
S&P 500 Timeline
1957-03-04Joined S&P 500
2014-05-01Removed from S&P 500
Data source:
Wikipedia · CC BY-SA 4.0 · Updated 2026-07-10